FI107696B - Lipidipartikkelinmuodostusmatriisi ja menetelmä sen valmistamiseksi - Google Patents

Lipidipartikkelinmuodostusmatriisi ja menetelmä sen valmistamiseksi Download PDF

Info

Publication number
FI107696B
FI107696B FI922452A FI922452A FI107696B FI 107696 B FI107696 B FI 107696B FI 922452 A FI922452 A FI 922452A FI 922452 A FI922452 A FI 922452A FI 107696 B FI107696 B FI 107696B
Authority
FI
Finland
Prior art keywords
lipid
polar
particle formation
formation matrix
matrix according
Prior art date
Application number
FI922452A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI922452A (fi
FI922452A0 (fi
Inventor
Bengt Hersloef
Martin Nicklasson
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of FI922452A publication Critical patent/FI922452A/fi
Publication of FI922452A0 publication Critical patent/FI922452A0/fi
Application granted granted Critical
Publication of FI107696B publication Critical patent/FI107696B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Colloid Chemistry (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Saccharide Compounds (AREA)
  • Fertilizers (AREA)
FI922452A 1990-09-28 1992-05-27 Lipidipartikkelinmuodostusmatriisi ja menetelmä sen valmistamiseksi FI107696B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9003100 1990-09-28
SE9003100A SE9003100D0 (sv) 1990-09-28 1990-09-28 Lipid formulation system
SE9100639 1991-09-24
PCT/SE1991/000639 WO1992005771A1 (en) 1990-09-28 1991-09-24 Lipid formulation system

Publications (3)

Publication Number Publication Date
FI922452A FI922452A (fi) 1992-05-27
FI922452A0 FI922452A0 (fi) 1992-05-27
FI107696B true FI107696B (fi) 2001-09-28

Family

ID=20380490

Family Applications (1)

Application Number Title Priority Date Filing Date
FI922452A FI107696B (fi) 1990-09-28 1992-05-27 Lipidipartikkelinmuodostusmatriisi ja menetelmä sen valmistamiseksi

Country Status (15)

Country Link
EP (1) EP0514506B1 (ja)
JP (1) JP2855594B2 (ja)
AT (1) ATE137667T1 (ja)
AU (1) AU645143B2 (ja)
CA (1) CA2069760C (ja)
DE (1) DE69119400T2 (ja)
DK (1) DK0514506T3 (ja)
ES (1) ES2088024T3 (ja)
FI (1) FI107696B (ja)
GR (1) GR3020674T3 (ja)
IE (1) IE62194B1 (ja)
NO (1) NO304729B1 (ja)
PT (1) PT99113B (ja)
SE (1) SE9003100D0 (ja)
WO (1) WO1992005771A1 (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260065A (en) * 1991-09-17 1993-11-09 Micro Vesicular Systems, Inc. Blended lipid vesicles
SE9200952D0 (sv) * 1992-03-27 1992-03-27 Kabi Pharmacia Ab Pharmaceutical carrier system containing defined lipids
SE9200951D0 (sv) * 1992-03-27 1992-03-27 Kabi Pharmacia Ab Pharmaceutical composition containing a defined lipid system
ES2158084T3 (es) * 1994-02-04 2001-09-01 Lipocore Holding Ab Preparaciones vehiculo lipofilicas.
DE4447287C1 (de) * 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
SE9703691D0 (sv) 1997-10-10 1997-10-10 Astra Ab Pharmaceutical compositions
GB2344520A (en) * 1998-12-08 2000-06-14 Phares Pharm Res Nv Pharmaceutical carriers comprising lipids and polymers
ES2226203T3 (es) 1998-12-23 2005-03-16 Idea Ag Formulacion mejorada para aplicacion topica no invasiva.
SE0000730D0 (sv) * 2000-03-06 2000-03-06 Scotia Holdings Plc Lipid carrier
SE0200475D0 (sv) * 2002-02-15 2002-02-15 Ltp Lipid Technologies Provide Oral farmaceutisk beredning
SE0201922D0 (sv) * 2002-06-20 2002-06-20 Ltp Lipid Technologies Provide Koagulationshindrande komposition (Anticoagulant Composition)
FR2868704B1 (fr) * 2004-04-07 2007-09-14 Ethypharm Sa Utilisation de lipides pour ameliorer la biodisponibilite de principes actifs proteiques en formulations injectables sous cutanees ou intra-musculaires
US20050232981A1 (en) 2004-04-15 2005-10-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
US20090041829A1 (en) * 2005-04-28 2009-02-12 Galenica Technology Ab Pharmaceutical dosage forms comprising a lipid phase
PT1933809E (pt) * 2005-10-11 2012-04-26 Yissum Res Dev Co Composições para administração por via nasal
BRPI0918652B1 (pt) 2008-09-17 2021-10-19 Chiasma, Inc. Composição farmacêutica compreendendo um meio hidrofóbico e uma forma sólida que compreende polipeptídeo e sal de ácido graxo de cadeia média, processo de produção da mesma e forma de dosagem oral
CN101926757B (zh) * 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法
US10238709B2 (en) 2015-02-03 2019-03-26 Chiasma, Inc. Method of treating diseases
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
CN117580560A (zh) * 2021-05-03 2024-02-20 Mcal治疗公司 微粉化脂质

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT8219012A0 (it) * 1982-01-06 1982-01-06 Ausonia Farma Srl Metodo per la somministrazione orale di sostanze sotto forma di liposomi, e relative formulazioni farmaceutiche.
GB8613811D0 (en) * 1986-06-06 1986-07-09 Phares Pharm Res Nv Composition & method
EP0158441B2 (en) * 1984-03-08 2001-04-04 Phares Pharmaceutical Research N.V. Liposome-forming composition
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
SE8603812D0 (sv) * 1986-09-12 1986-09-12 Draco Ab Administration of liposomes to mammals
EP0280394B1 (en) * 1987-01-27 1994-12-14 Vestar, Inc. Phospholipid delivery vehicle for aqueous-insoluble active ingredients

Also Published As

Publication number Publication date
AU8710591A (en) 1992-04-28
GR3020674T3 (en) 1996-10-31
PT99113A (pt) 1992-08-31
FI922452A (fi) 1992-05-27
FI922452A0 (fi) 1992-05-27
ATE137667T1 (de) 1996-05-15
DE69119400T2 (de) 1996-12-05
IE913246A1 (en) 1992-04-08
IE62194B1 (en) 1994-12-28
DK0514506T3 (da) 1996-08-12
ES2088024T3 (es) 1996-08-01
PT99113B (pt) 1999-02-26
AU645143B2 (en) 1994-01-06
JPH05503711A (ja) 1993-06-17
WO1992005771A1 (en) 1992-04-16
CA2069760A1 (en) 1992-03-29
JP2855594B2 (ja) 1999-02-10
CA2069760C (en) 1998-02-10
NO922084L (no) 1992-05-26
DE69119400D1 (de) 1996-06-13
NO922084D0 (no) 1992-05-26
SE9003100D0 (sv) 1990-09-28
EP0514506B1 (en) 1996-05-08
NO304729B1 (no) 1999-02-08
EP0514506A1 (en) 1992-11-25

Similar Documents

Publication Publication Date Title
FI107696B (fi) Lipidipartikkelinmuodostusmatriisi ja menetelmä sen valmistamiseksi
US5665379A (en) Lipid particle forming matrix, preparation and use thereof
Angelova et al. Liquid crystalline nanostructures as pegylated reservoirs of omega-3 polyunsaturated fatty acids: Structural insights toward delivery formulations against neurodegenerative disorders
Laouini et al. Preparation, characterization and applications of liposomes: state of the art
Hippalgaonkar et al. Injectable lipid emulsions—advancements, opportunities and challenges
Lawrence Microemulsions as drug delivery vehicles
US20020048596A1 (en) Preparation for the transport of an active substance across barriers
JP5142989B2 (ja) 脂質とスチレン及びマレイン酸の共重合体とを含む組成物
JPH0347527A (ja) 水相中に油粒子のナノエマルジヨンを製造する方法、薬学および化粧品調剤の製法および細胞培養用栄養溶液の製法
AU8118498A (en) Preparation of pharmaceutical compositions
JP2004524368A (ja) 低い水溶性を有する生物学的に活性な化合物を可溶化するための方法および組成物
CA2268670A1 (en) Preparation for transporting active ingredients through barriers
Ma et al. A highly stable norcantharidin loaded lipid microspheres: preparation, biodistribution and targeting evaluation
Ray et al. Noisomes: as novel vesicular drug delivery system
Kasagi et al. Optimization of dihydrosphingomyelin/cholesterol mol ratio in topotecan-loaded liposomes to enhance drug retention and plasma half-life by understanding physicochemical and thermodynamic properties of the lipid membrane
Patel et al. Niosome: a vesicular drug delivery tool
JPH07108166A (ja) リポソーム
Mehta et al. Microemulsions: A potential novel drug delivery system
Cai et al. Lipid nanoparticle steric stabilization roadmap
AU2016700A (en) A pharmaceutical composition comprising cyclosporin in a lipid carrier
CN112190504B (zh) 一种含有玫瑰精油的长效液体凝胶及其制备方法和应用
Parmar et al. Conceptual aspects of vesicular drug delivery system with special reference to niosome
JPH10510207A (ja) 隔離剤
RU2740553C2 (ru) Способ получения липосомальной формы бетулина, обладающей гепатопротекторной активностью
Nadaf et al. Novel liposome derived nanoparticulate drug delivery system: fabrication and prospects

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: PHARMACIA AB